Cargando…
An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy
Introduction: Patients with coronavirus disease 2019 (COVID-19) have an increased risk for venous thromboembolic events. Thrombotic events contribute to the morbidity and mortality associated with COVID-19 infection, and have prompted investigation into strategies for mitigating thrombosis risk in p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701434/ http://dx.doi.org/10.1182/blood-2021-154453 |
_version_ | 1784620999833026560 |
---|---|
author | Kaufman, Adrienne Kusne, Yael Klanderman, Molly Kosiorek, Heidi E. Oliver, Thomas Gonzalez-Velez, Miguel McBane, Robert D. Wysokinski, Waldemar E. Houghton, Damon E. Padrnos, Leslie |
author_facet | Kaufman, Adrienne Kusne, Yael Klanderman, Molly Kosiorek, Heidi E. Oliver, Thomas Gonzalez-Velez, Miguel McBane, Robert D. Wysokinski, Waldemar E. Houghton, Damon E. Padrnos, Leslie |
author_sort | Kaufman, Adrienne |
collection | PubMed |
description | Introduction: Patients with coronavirus disease 2019 (COVID-19) have an increased risk for venous thromboembolic events. Thrombotic events contribute to the morbidity and mortality associated with COVID-19 infection, and have prompted investigation into strategies for mitigating thrombosis risk in patients hospitalized with COVID-19 infection. Our team reviewed the charts of patients hospitalized with COVID-19 pneumonia at a tertiary hospital in metropolitan Phoenix Arizona between 2020-2021, to assess frequency and efficacy of utilizing a VTE prophylaxis algorithm designed to prevent thrombosis in patients infected with COVID-19. Methods: A total of 846 patients were retrospectively evaluated to determine if they were treated with guideline-appropriate anticoagulation while hospitalized with COVID-19, as well as if they developed venous or arterial thrombotic events, or major or minor bleeds. 317 patients were excluded for taking therapeutic anticoagulation prior to admission, or for having a COVID-19 diagnosis >7 days after admission. Appropriate anticoagulation was determined by an institutionally designed COVID-19 thromboprophylaxis algorithm, based on platelet count, d-dimer, bleeding risk, and level of medical care required. Regimen options included: no anticoagulation, prophylactic enoxaparin (40 mg SQ daily) or heparin in the setting of kidney dysfunction, weight-based dosing of enoxaparin (40 mg SQ BID if BMI>40), intermediate intensity enoxaparin without thrombus (30 mg BID if BMI<40, or 40 mg BID if BMI>40), and therapeutic anticoagulation (for example enoxaparin 1 mg/kg BID) with thrombus. Demographics: Demographic data and clinical characteristics were collected for 529 patients. Average age was 59 years old, and the majority were men (58.4%). Most patients were White (58.3%), followed by Hispanic (17.8%), or Native American (15.7%). Fewer patients had a normal BMI (21.3%; BMI 18.5 - 24.9) compared to those who were overweight (31.2%; BMI 25-29.9) or obese (43.1% BMI > 30). Other comorbidities included Type 1 or Type 2 diabetes mellitus (N= 172, 32.5%), hypertension (N = 271, 51.2%), and hyperlipidemia (N = 176, 33.3%). Results: A total of 42 patients (8%), were diagnosed with a venous thrombosis during hospitalization. Patients admitted to the ICU were significantly more likely to have a thrombotic event of any type compared to non-ICU patients (21.6% to 5.7%; p < 0.001). Specifically, critically ill patients had higher incidences of deep vein thrombosis (9.5% to 0.7%), pulmonary emboli (8.1% to 4.8%), and superficial thrombi (2.7% to 0.2%). Only 1.1% of patients (6/529) experienced any bleeding, of which 3 were classified as a major bleed. Discussion: Among patients hospitalized at our institution with COVID-19, the majority were anticoagulated appropriately according to the COVID-19 thromboprophylaxis algorithm. Overall incidence of thrombosis in the study population was 8%. A significantly higher percent of critically ill patients had thrombi, supporting reports of correlation between severity of illness and thrombosis risk. The two regimens of anticoagulation least adhered to were weight-based and intermediate-based dosing, likely reflecting a departure from the hospital's thromboprophylaxis regimens prior to COVID-19 pandemic. Further studies are needed to characterize whether identifiable risk factors correlate with the incidence of thrombosis, and whether treatment with lower than recommended doses of anticoagulation, based on the COVID-19 thromboprophylaxis algorithm, were associated with thrombosis. DISCLOSURES: No relevant conflicts of interest to declare. |
format | Online Article Text |
id | pubmed-8701434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society of Hematology. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87014342021-12-28 An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy Kaufman, Adrienne Kusne, Yael Klanderman, Molly Kosiorek, Heidi E. Oliver, Thomas Gonzalez-Velez, Miguel McBane, Robert D. Wysokinski, Waldemar E. Houghton, Damon E. Padrnos, Leslie Blood 331.Thrombosis Introduction: Patients with coronavirus disease 2019 (COVID-19) have an increased risk for venous thromboembolic events. Thrombotic events contribute to the morbidity and mortality associated with COVID-19 infection, and have prompted investigation into strategies for mitigating thrombosis risk in patients hospitalized with COVID-19 infection. Our team reviewed the charts of patients hospitalized with COVID-19 pneumonia at a tertiary hospital in metropolitan Phoenix Arizona between 2020-2021, to assess frequency and efficacy of utilizing a VTE prophylaxis algorithm designed to prevent thrombosis in patients infected with COVID-19. Methods: A total of 846 patients were retrospectively evaluated to determine if they were treated with guideline-appropriate anticoagulation while hospitalized with COVID-19, as well as if they developed venous or arterial thrombotic events, or major or minor bleeds. 317 patients were excluded for taking therapeutic anticoagulation prior to admission, or for having a COVID-19 diagnosis >7 days after admission. Appropriate anticoagulation was determined by an institutionally designed COVID-19 thromboprophylaxis algorithm, based on platelet count, d-dimer, bleeding risk, and level of medical care required. Regimen options included: no anticoagulation, prophylactic enoxaparin (40 mg SQ daily) or heparin in the setting of kidney dysfunction, weight-based dosing of enoxaparin (40 mg SQ BID if BMI>40), intermediate intensity enoxaparin without thrombus (30 mg BID if BMI<40, or 40 mg BID if BMI>40), and therapeutic anticoagulation (for example enoxaparin 1 mg/kg BID) with thrombus. Demographics: Demographic data and clinical characteristics were collected for 529 patients. Average age was 59 years old, and the majority were men (58.4%). Most patients were White (58.3%), followed by Hispanic (17.8%), or Native American (15.7%). Fewer patients had a normal BMI (21.3%; BMI 18.5 - 24.9) compared to those who were overweight (31.2%; BMI 25-29.9) or obese (43.1% BMI > 30). Other comorbidities included Type 1 or Type 2 diabetes mellitus (N= 172, 32.5%), hypertension (N = 271, 51.2%), and hyperlipidemia (N = 176, 33.3%). Results: A total of 42 patients (8%), were diagnosed with a venous thrombosis during hospitalization. Patients admitted to the ICU were significantly more likely to have a thrombotic event of any type compared to non-ICU patients (21.6% to 5.7%; p < 0.001). Specifically, critically ill patients had higher incidences of deep vein thrombosis (9.5% to 0.7%), pulmonary emboli (8.1% to 4.8%), and superficial thrombi (2.7% to 0.2%). Only 1.1% of patients (6/529) experienced any bleeding, of which 3 were classified as a major bleed. Discussion: Among patients hospitalized at our institution with COVID-19, the majority were anticoagulated appropriately according to the COVID-19 thromboprophylaxis algorithm. Overall incidence of thrombosis in the study population was 8%. A significantly higher percent of critically ill patients had thrombi, supporting reports of correlation between severity of illness and thrombosis risk. The two regimens of anticoagulation least adhered to were weight-based and intermediate-based dosing, likely reflecting a departure from the hospital's thromboprophylaxis regimens prior to COVID-19 pandemic. Further studies are needed to characterize whether identifiable risk factors correlate with the incidence of thrombosis, and whether treatment with lower than recommended doses of anticoagulation, based on the COVID-19 thromboprophylaxis algorithm, were associated with thrombosis. DISCLOSURES: No relevant conflicts of interest to declare. American Society of Hematology. Published by Elsevier Inc. 2021-11-23 2021-12-24 /pmc/articles/PMC8701434/ http://dx.doi.org/10.1182/blood-2021-154453 Text en Copyright © 2021 American Society of Hematology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | 331.Thrombosis Kaufman, Adrienne Kusne, Yael Klanderman, Molly Kosiorek, Heidi E. Oliver, Thomas Gonzalez-Velez, Miguel McBane, Robert D. Wysokinski, Waldemar E. Houghton, Damon E. Padrnos, Leslie An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy |
title | An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy |
title_full | An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy |
title_fullStr | An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy |
title_full_unstemmed | An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy |
title_short | An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy |
title_sort | inpatient covid-19 prophylaxis protocol and its outcomes: adherence and efficacy |
topic | 331.Thrombosis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701434/ http://dx.doi.org/10.1182/blood-2021-154453 |
work_keys_str_mv | AT kaufmanadrienne aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT kusneyael aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT klandermanmolly aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT kosiorekheidie aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT oliverthomas aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT gonzalezvelezmiguel aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT mcbanerobertd aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT wysokinskiwaldemare aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT houghtondamone aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT padrnosleslie aninpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT kaufmanadrienne inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT kusneyael inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT klandermanmolly inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT kosiorekheidie inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT oliverthomas inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT gonzalezvelezmiguel inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT mcbanerobertd inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT wysokinskiwaldemare inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT houghtondamone inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy AT padrnosleslie inpatientcovid19prophylaxisprotocolanditsoutcomesadherenceandefficacy |